Summary
12.22 6.62(118.21%)09/13/2024
Singular Genomics Systems Inc (OMIC)
Singular Genomics Systems Inc (OMIC)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 118.21 | -8.58 | -20.65 | 1,561.76 | 965.64 | 1,194.09 | 0.00 | -77.53 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 12.22 | |
| Open | 8.70 | |
| High | 12.70 | |
| Low | 8.70 | |
| Volume | 2,751,131 | |
| Change | 6.62 | |
| Change % | 118.21 | |
| Avg Volume (20 Days) | 7,676 | |
| Volume/Avg Volume (20 Days) Ratio | 358.41 | |
| 52 Week Range | 0.27 - 12.37 | |
| Price vs 52 Week High | -1.21% | |
| Price vs 52 Week Low | 4,425.93% | |
| Range | 2.36 | |
| Gap Up/Down | -0.28 | |
Fundamentals | ||
| Market Capitalization (Mln) | 31 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 27.67 | |
| Book Value | 4.8940 | |
| Earnings Per Share | -2.7500 | |
| EPS Estimate Current Quarter | -0.2400 | |
| EPS Estimate Next Quarter | -0.2600 | |
| EPS Estimate Current Year | -1.7700 | |
| EPS Estimate Next Year | -1.3200 | |
| Diluted EPS (TTM) | -2.7500 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.2432 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 72,058,496 | |
| Shares Float | 33,301,846 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 20.96 | |
| Institutions (%) | 63.68 | |
09/12 16:31 EST - globenewswire.com
Singular Genomics Receives Non-Binding Acquisition Proposal from Deerfield
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today that it has received a non-binding proposal from Deerfield Management Company, L.P. and certain affiliated funds (collectively, “Deerfield”), to acquire all of the Company's outstanding shares of common stock that are not already owned by Deerfield for $10.00 per share in cash. Deerfield, an existing stockholder of the Company, indicated in its letter that it intends to invite other major stockholders and existing management to rollover their shares of common stock into the new company.
Singular Genomics Receives Non-Binding Acquisition Proposal from Deerfield
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today that it has received a non-binding proposal from Deerfield Management Company, L.P. and certain affiliated funds (collectively, “Deerfield”), to acquire all of the Company's outstanding shares of common stock that are not already owned by Deerfield for $10.00 per share in cash. Deerfield, an existing stockholder of the Company, indicated in its letter that it intends to invite other major stockholders and existing management to rollover their shares of common stock into the new company.
08/13 21:44 EST - seekingalpha.com
Singular Genomics Systems, Inc. (OMIC) Q2 2024 Earnings Call Transcript
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder, Chair and CEO Dalen Meeter - CFO Conference Call Participants Daniel Brennan - TD Cowen Matthew Sykes - Goldman Sachs Operator Greeting. Welcome to the Singular Genomics Second Quarter and Business Update Call.
Singular Genomics Systems, Inc. (OMIC) Q2 2024 Earnings Call Transcript
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder, Chair and CEO Dalen Meeter - CFO Conference Call Participants Daniel Brennan - TD Cowen Matthew Sykes - Goldman Sachs Operator Greeting. Welcome to the Singular Genomics Second Quarter and Business Update Call.
07/30 17:05 EST - globenewswire.com
Singular Genomics to Report Second Quarter 2024 Financial Results on August 13, 2024
SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter ended June 30, 2024 after the market close on Tuesday, August 13, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Singular Genomics to Report Second Quarter 2024 Financial Results on August 13, 2024
SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter ended June 30, 2024 after the market close on Tuesday, August 13, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
07/15 16:05 EST - globenewswire.com
Singular Genomics Regains Compliance with Nasdaq Minimum Bid Price Requirement
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it received formal notice from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.
Singular Genomics Regains Compliance with Nasdaq Minimum Bid Price Requirement
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it received formal notice from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.
06/24 03:32 EST - benzinga.com
Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday
With U.S. stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday
With U.S. stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
06/21 16:05 EST - globenewswire.com
Singular Genomics Announces 1-for-30 Reverse Stock Split
SAN DIEGO, June 21, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that on June 26, 2024, effective at 12:01 a.m. Eastern Time, it will effectuate a 1-for-30 reverse split of its common stock. The Company's common stock will begin trading on a split-adjusted basis when the market opens on June 26, 2024 under its current trading symbol “OMIC”. The CUSIP number of the Company's common stock following the reverse stock split will be 82933R 308.
Singular Genomics Announces 1-for-30 Reverse Stock Split
SAN DIEGO, June 21, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that on June 26, 2024, effective at 12:01 a.m. Eastern Time, it will effectuate a 1-for-30 reverse split of its common stock. The Company's common stock will begin trading on a split-adjusted basis when the market opens on June 26, 2024 under its current trading symbol “OMIC”. The CUSIP number of the Company's common stock following the reverse stock split will be 82933R 308.
05/29 16:05 EST - globenewswire.com
Singular Genomics to Present at the Goldman Sachs Global Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced plans to present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, Florida.
Singular Genomics to Present at the Goldman Sachs Global Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced plans to present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, Florida.
05/23 09:17 EST - seekingalpha.com
Lab Instrument Industry Update - New Commercial Entrants
Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.
Lab Instrument Industry Update - New Commercial Entrants
Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.
05/14 20:04 EST - seekingalpha.com
Singular Genomics Systems, Inc. (OMIC) Q1 2024 Earnings Call Transcript
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q1 2024 Results Conference Call May 14, 2024 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder, Chair and CEO Dalen Meeter - CFO Conference Call Participants Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Operator Good afternoon, everyone, and welcome to the Singular Genomics Systems Inc. First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Singular Genomics Systems, Inc. (OMIC) Q1 2024 Earnings Call Transcript
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q1 2024 Results Conference Call May 14, 2024 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder, Chair and CEO Dalen Meeter - CFO Conference Call Participants Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Operator Good afternoon, everyone, and welcome to the Singular Genomics Systems Inc. First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
05/14 16:05 EST - globenewswire.com
Singular Genomics Reports Recent Highlights and First Quarter 2024 Financial Results
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the first quarter ended March 31, 2024.
Singular Genomics Reports Recent Highlights and First Quarter 2024 Financial Results
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the first quarter ended March 31, 2024.
03/18 19:07 EST - seekingalpha.com
Singular Genomics Systems, Inc. (OMIC) Q4 2023 Earnings Call Transcript
Singular Genomics Systems, Inc. (OMIC) Q4 2023 Earnings Call Transcript
Singular Genomics Systems, Inc. (OMIC) Q4 2023 Earnings Call Transcript
Singular Genomics Systems, Inc. (OMIC) Q4 2023 Earnings Call Transcript
03/18 16:05 EST - globenewswire.com
Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the fourth quarter and full year ended December 31, 2023.
Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the fourth quarter and full year ended December 31, 2023.
03/04 16:05 EST - globenewswire.com
Singular Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Monday, March 18, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Singular Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Monday, March 18, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
02/05 10:55 EST - globenewswire.com
Singular Genomics Showcases New G4X™ Spatial Sequencer at AGBT and Announces Significant Advances in Throughput, Quality, and Usability for G4® Sequencing Platform
SAN DIEGO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced groundbreaking new products and capabilities at the Advances of Genome Biology and Technology (AGBT) conference in Orlando, Florida.
Singular Genomics Showcases New G4X™ Spatial Sequencer at AGBT and Announces Significant Advances in Throughput, Quality, and Usability for G4® Sequencing Platform
SAN DIEGO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced groundbreaking new products and capabilities at the Advances of Genome Biology and Technology (AGBT) conference in Orlando, Florida.
02/05 10:54 EST - globenewswire.com
Singular Genomics Unveils G4X™ Spatial Sequencer, Transforming the Landscape of In Situ Multiomic Analysis
SAN DIEGO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today unveiled the G4X™ Spatial Sequencer. The G4X is designed to offer high-throughput in situ direct sequencing of RNA (Direct-Seq™), targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues. The G4X will share the same platform as the existing G4® sequencer and is expected to be the industry's first dual-purpose instrument offering both traditional NGS and tissue-based spatial sequencing capabilities. With the addition of high-throughput multiomics and novel Direct-Seq technology to its portfolio with the G4X, Singular is positioned to become the only company worldwide to offer in situ spatial sequencing of tissues and NGS on the same instrument.
Singular Genomics Unveils G4X™ Spatial Sequencer, Transforming the Landscape of In Situ Multiomic Analysis
SAN DIEGO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today unveiled the G4X™ Spatial Sequencer. The G4X is designed to offer high-throughput in situ direct sequencing of RNA (Direct-Seq™), targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues. The G4X will share the same platform as the existing G4® sequencer and is expected to be the industry's first dual-purpose instrument offering both traditional NGS and tissue-based spatial sequencing capabilities. With the addition of high-throughput multiomics and novel Direct-Seq technology to its portfolio with the G4X, Singular is positioned to become the only company worldwide to offer in situ spatial sequencing of tissues and NGS on the same instrument.
01/07 17:00 EST - globenewswire.com
Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2023 Revenue
SAN DIEGO, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced instrument shipments and preliminary unaudited revenue for the fourth quarter of 2023.
Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2023 Revenue
SAN DIEGO, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced instrument shipments and preliminary unaudited revenue for the fourth quarter of 2023.
11/14 21:10 EST - seekingalpha.com
Singular Genomics Systems, Inc. (OMIC) Q3 2023 Earnings Call Transcript
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - CEO, Founder & Chairman Dalen Meeter - CFO Conference Call Participants Dan Brennan - TD Cowen Matt Sykes - Goldman Sachs John Sourbeer - UBS Operator Greetings. Welcome to the Singular Genomics Systems, Inc. Third Quarter 2023 Earnings Conference Call.
Singular Genomics Systems, Inc. (OMIC) Q3 2023 Earnings Call Transcript
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - CEO, Founder & Chairman Dalen Meeter - CFO Conference Call Participants Dan Brennan - TD Cowen Matt Sykes - Goldman Sachs John Sourbeer - UBS Operator Greetings. Welcome to the Singular Genomics Systems, Inc. Third Quarter 2023 Earnings Conference Call.
11/14 16:01 EST - globenewswire.com
Singular Genomics Reports Recent Highlights and Third Quarter 2023 Financial Results
SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2023.
Singular Genomics Reports Recent Highlights and Third Quarter 2023 Financial Results
SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2023.
10/24 16:22 EST - globenewswire.com
Singular Genomics to Report Third Quarter 2023 Financial Results on November 14, 2023
SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2023 after the market close on Tuesday, November 14, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Singular Genomics to Report Third Quarter 2023 Financial Results on November 14, 2023
SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2023 after the market close on Tuesday, November 14, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
09/20 11:28 EST - investorplace.com
Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now
The biotech sector never fails to offer up stocks full of massive issues at any given time. Developing novel therapeutic devices and pharmaceuticals is, after all, very expensive.
Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now
The biotech sector never fails to offer up stocks full of massive issues at any given time. Developing novel therapeutic devices and pharmaceuticals is, after all, very expensive.